Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Expert panelists share insight on molecular testing practices across all subtypes of non–small cell lung cancer to optimally inform treatment decisions.

A brief review of real-world data behind molecular profiling in non–small cell lung cancer, followed by a discussion on barriers to testing and uptake.

A focused discussion on the use of molecular profiling in early-stage non–small cell lung cancer to inform decisions on adjuvant and neoadjuvant strategies.

Expert oncologists briefly highlight the role of liquid biopsy in the setting of advanced-stage non–small cell lung cancer.

Shifting focus to early-stage NSCLC, expert panelists define the role of resection and consider when it is appropriate to utilize adjuvant radiation therapy.

Shared insight on the role and selection of adjuvant chemotherapy for patients with early-stage non–small cell lung cancer.

Advances in Testing and Targeted Therapy for NSCLC: Translating Evidence to Clinical Practice

Expert perspectives on use of immunotherapy in the adjuvant setting of early-stage NSCLC in light of data from IMpower010 and PEARLS.

Comprehensive review on various neoadjuvant strategies under review in the setting of resectable non–small cell lung cancer.

Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression.

A brief review of suboptimal outcomes with immunotherapy in the setting of EGFR-mutant advanced non–small cell lung cancer.

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.